Abstract | INTRODUCTION: CASE PRESENTATION: The present report describes the case of an 80-year-old white man with an intermediate to low early mortality risk of pulmonary embolism. He was successfully treated with rivaroxaban (administered orally as monotherapy), demonstrating rapid benefit without any adverse events. CONCLUSION:
Rivaroxaban, particularly in the acute phase of pulmonary embolism, may be considered an effective and safe therapeutic choice even in elderly patients, a population less represented in clinical trials.
|
Authors | Maurizio Menichetti, Sebastiano Rosso, Elisa Menegatti, Maria Pazzaglia |
Journal | Journal of medical case reports
(J Med Case Rep)
Vol. 9
Pg. 274
(Nov 26 2015)
ISSN: 1752-1947 [Electronic] England |
PMID | 26607201
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Rivaroxaban
|
Topics |
- Administration, Oral
- Aged, 80 and over
- Anticoagulants
(administration & dosage)
- Dyspnea
(etiology)
- Humans
- Male
- Pulmonary Embolism
(complications, drug therapy, physiopathology)
- Risk Assessment
- Rivaroxaban
(administration & dosage)
- Treatment Outcome
|